vorinostat has been researched along with HIV Coinfection in 53 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Excerpt | Relevance | Reference |
---|---|---|
"Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0." | 3.11 | Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. ( Aga, E; Archin, N; Bosch, RJ; Chomont, N; Connick, E; Coxen, K; Deeks, S; Dobrowolski, C; Ehui, L; Gandhi, M; Gandhi, RT; Giguel, F; Godfrey, C; Hosey, L; Howell, BJ; Karn, J; Kuritzkes, DR; Ma, Q; Morse, GD; Scully, EP; Sieg, SF; Squires, KE; Starr, K; Tsibris, A; Wu, G, 2022) |
"Vorinostat was safe and well tolerated and there were no dose modifications or study drug discontinuations." | 2.79 | Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. ( Ahlers, J; Brown, G; Cameron, MJ; Cameron, PU; Chomont, N; Deeks, SG; Elliott, JH; Fromentin, R; Ghneim, K; Hazuda, DJ; Hoy, JF; Johnstone, RW; Lewin, SR; Martin, BP; McMahon, J; Odevall, L; Palmer, S; Prince, MH; Procopio, FA; Roney, J; Sékaly, RP; Sinclair, E; Smith, MZ; Solomon, A; Spelman, T; Velayudham, P; Watson, J; Wightman, F; Zeidan, J, 2014) |
"The combination of prolonged high-dose disulfiram and vorinostat was not safe in PWH on ART and should not be pursued despite evidence of latency reversal." | 1.72 | Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. ( Blennow, K; Bumpus, N; Burger, D; Chang, J; Dantanarayana, A; Evans, VA; Fisher, K; Gisslen, M; Hagenauer, M; Heck, CJS; Howell, BJ; Lau, JSY; Lee, S; Lewin, SR; McMahon, JH; Palmer, S; Rasmussen, TA; Solomon, A; Symons, J; Tennakoon, S; Wu, G; Zerbato, JM; Zetterberg, HH; Zuck, P, 2022) |
"Soraphen A is a myxobacterial metabolite that blocks the acetyl-coenzyme A carboxylase of the host and was previously identified as a novel HIV inhibitor." | 1.46 | The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition. ( Bosch, M; Brönstrup, M; Diez, J; Fleta-Soriano, E; Lopez-Iglesias, C; Lorca Oró, C; Martínez, JP; Meyerhans, A; Mirambeau, G; Pol, A; Sadiq, SK; Smutná, K, 2017) |
" We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency." | 1.46 | Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. ( Allard, B; Archin, NM; Clutton, G; Eron, J; Gay, CL; Goonetilleke, N; Kashuba, AD; Kirchherr, JL; Kuruc, JD; Margolis, DM; Sholtis, K; Stuelke, E; Sung, JA; Xu, Y, 2017) |
"We recorded a total of 31 adverse events (26 grade 1 and five grade 2) in all study participants (n = 20)." | 1.46 | No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. ( Dantanarayana, A; Elliott, JH; Hagenauer, M; Hoy, JF; Lewin, SR; McMahon, J; Mota, TM; Prince, HM; Purcell, DFJ; Rasmussen, TA; Rhodes, A; Roney, J; Spelman, T; Tennakoon, S; Wightman, F, 2017) |
"Vorinostat does not enhance viral fusion with cells but rather enhances the kinetics and efficiency of postentry viral events, including reverse transcription, nuclear import, and integration, and enhances viral production in a spreading-infection assay." | 1.40 | The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. ( Dobrowolski, C; Haqqani, AA; Karn, J; Lucera, MB; Mao, H; Tabler, CO; Tilton, CA; Tilton, JC, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (3.77) | 29.6817 |
2010's | 36 (67.92) | 24.3611 |
2020's | 15 (28.30) | 2.80 |
Authors | Studies |
---|---|
Mejia, EJ | 1 |
Loveridge, ST | 1 |
Stepan, G | 1 |
Tsai, A | 1 |
Jones, GS | 1 |
Barnes, T | 1 |
White, KN | 1 |
Drašković, M | 1 |
Tenney, K | 1 |
Tsiang, M | 1 |
Geleziunas, R | 1 |
Cihlar, T | 1 |
Pagratis, N | 1 |
Tian, Y | 1 |
Yu, H | 1 |
Crews, P | 1 |
Lopes, JR | 1 |
Chiba, DE | 1 |
Dos Santos, JL | 1 |
Gay, CL | 5 |
James, KS | 2 |
Tuyishime, M | 2 |
Falcinelli, SD | 3 |
Joseph, SB | 1 |
Moeser, MJ | 1 |
Allard, B | 4 |
Kirchherr, JL | 3 |
Clohosey, M | 1 |
Raines, SLM | 1 |
Montefiori, DC | 1 |
Shen, X | 1 |
Gorelick, RJ | 2 |
Gama, L | 1 |
McDermott, AB | 1 |
Koup, RA | 1 |
Mascola, JR | 1 |
Floris-Moore, M | 1 |
Kuruc, JD | 6 |
Ferrari, G | 2 |
Eron, JJ | 3 |
Archin, NM | 10 |
Margolis, DM | 13 |
McMahon, JH | 2 |
Evans, VA | 1 |
Lau, JSY | 1 |
Symons, J | 1 |
Zerbato, JM | 2 |
Chang, J | 1 |
Solomon, A | 3 |
Tennakoon, S | 2 |
Dantanarayana, A | 3 |
Hagenauer, M | 3 |
Lee, S | 1 |
Palmer, S | 3 |
Fisher, K | 1 |
Bumpus, N | 1 |
Heck, CJS | 1 |
Burger, D | 1 |
Wu, G | 4 |
Zuck, P | 1 |
Howell, BJ | 3 |
Zetterberg, HH | 1 |
Blennow, K | 1 |
Gisslen, M | 1 |
Rasmussen, TA | 5 |
Lewin, SR | 11 |
Scully, EP | 1 |
Aga, E | 1 |
Tsibris, A | 1 |
Archin, N | 3 |
Starr, K | 2 |
Ma, Q | 1 |
Morse, GD | 1 |
Squires, KE | 1 |
Hosey, L | 2 |
Sieg, SF | 1 |
Ehui, L | 1 |
Giguel, F | 1 |
Coxen, K | 1 |
Dobrowolski, C | 2 |
Gandhi, M | 1 |
Deeks, S | 1 |
Chomont, N | 2 |
Connick, E | 1 |
Godfrey, C | 2 |
Karn, J | 2 |
Kuritzkes, DR | 2 |
Bosch, RJ | 3 |
Gandhi, RT | 1 |
Day, S | 1 |
Mathews, A | 1 |
Blumberg, M | 1 |
Vu, T | 1 |
Rennie, S | 1 |
Tucker, JD | 1 |
Fidler, S | 1 |
Stöhr, W | 1 |
Pace, M | 1 |
Dorrell, L | 1 |
Lever, A | 1 |
Pett, S | 1 |
Kinloch-de Loes, S | 1 |
Fox, J | 1 |
Clarke, A | 1 |
Nelson, M | 1 |
Thornhill, J | 1 |
Khan, M | 1 |
Fun, A | 1 |
Bandara, M | 1 |
Kelly, D | 1 |
Kopycinski, J | 1 |
Hanke, T | 1 |
Yang, H | 1 |
Bennett, R | 1 |
Johnson, M | 1 |
Howell, B | 1 |
Barnard, R | 2 |
Kaye, S | 1 |
Wills, M | 1 |
Babiker, A | 1 |
Frater, J | 2 |
Dubé, K | 1 |
Barr, L | 1 |
Evans, D | 1 |
Hoffman, E | 1 |
Campbell, DM | 1 |
Simoni, J | 1 |
Sugarman, J | 1 |
Sauceda, J | 1 |
Brown, B | 1 |
Diepstra, KL | 1 |
Wohl, DA | 1 |
Gandhi, R | 1 |
Scully, E | 1 |
Warren, JA | 1 |
Reifeis, SA | 1 |
Dewey, MG | 1 |
Helms, A | 1 |
Stuelke, E | 2 |
Gamble, A | 1 |
Plachco, A | 1 |
Hudgens, M | 1 |
Garrido, C | 4 |
Goonetilleke, N | 3 |
DeBenedette, MA | 1 |
Tcherepanova, IY | 1 |
Nicolette, CA | 1 |
De la Torre-Tarazona, HE | 1 |
Jiménez, R | 1 |
Bueno, P | 1 |
Camarero, S | 1 |
Román, L | 1 |
Fernández-García, JL | 1 |
Beltrán, M | 1 |
Nothias, LF | 1 |
Cachet, X | 1 |
Paolini, J | 1 |
Litaudon, M | 1 |
Alcami, J | 1 |
Bedoya, LM | 1 |
Maxwell, JW | 1 |
Nefedov, A | 1 |
Dorfmeier, C | 1 |
Dewey, M | 1 |
Webber, AL | 1 |
Hazuda, DJ | 3 |
Barnard, RJO | 1 |
Ramos, JC | 1 |
Sparano, JA | 1 |
Chadburn, A | 1 |
Reid, EG | 1 |
Ambinder, RF | 1 |
Siegel, ER | 1 |
Moore, PC | 1 |
Rubinstein, PG | 1 |
Durand, CM | 2 |
Cesarman, E | 1 |
Aboulafia, D | 1 |
Baiocchi, R | 1 |
Ratner, L | 1 |
Kaplan, L | 1 |
Capoferri, AA | 1 |
Lee, JY | 1 |
Mitsuyasu, R | 1 |
Noy, A | 1 |
Piekna-Przybylska, D | 1 |
Bambara, RA | 1 |
Maggirwar, SB | 1 |
Dewhurst, S | 1 |
Witzig, TE | 1 |
Feng, Z | 1 |
Yang, Z | 1 |
Gao, X | 1 |
Xue, Y | 1 |
Wang, X | 1 |
Khoury, G | 2 |
Zhao, W | 1 |
Gartner, MJ | 1 |
Pascoe, RD | 1 |
Rhodes, A | 2 |
Gooey, M | 1 |
Anderson, J | 2 |
Bacchetti, P | 1 |
Deeks, SG | 4 |
McMahon, J | 4 |
Roche, M | 1 |
Purcell, DF | 1 |
Fleta-Soriano, E | 1 |
Smutná, K | 1 |
Martínez, JP | 1 |
Lorca Oró, C | 1 |
Sadiq, SK | 1 |
Mirambeau, G | 1 |
Lopez-Iglesias, C | 1 |
Bosch, M | 1 |
Pol, A | 1 |
Brönstrup, M | 1 |
Diez, J | 1 |
Meyerhans, A | 1 |
Desimio, MG | 1 |
Giuliani, E | 1 |
Doria, M | 1 |
Sung, JA | 3 |
Clutton, G | 2 |
Sholtis, K | 2 |
Xu, Y | 2 |
Kashuba, AD | 2 |
Eron, J | 1 |
Kirchherr, J | 2 |
Nordstrom, JL | 1 |
Bollard, CM | 2 |
Kim, Y | 1 |
Anderson, JL | 1 |
Jiang, G | 1 |
Nguyen, D | 1 |
Yukl, SA | 2 |
Méndez-Lagares, G | 1 |
Tang, Y | 1 |
Elsheikh, MM | 1 |
Thompson, GR | 1 |
Hartigan-O'Connor, DJ | 1 |
Wong, JK | 2 |
Dandekar, S | 1 |
Abad-Fernandez, M | 1 |
Pollara, JJ | 1 |
Soriano-Sarabia, N | 2 |
White, CH | 1 |
Beliakova-Bethell, N | 1 |
Lada, SM | 1 |
Breen, MS | 1 |
Hurst, TP | 1 |
Spina, CA | 2 |
Richman, DD | 2 |
Magiorkinis, G | 1 |
Woelk, CH | 1 |
Andersen, RJ | 1 |
Ntie-Kang, F | 1 |
Tietjen, I | 1 |
Chandra, PK | 1 |
Gerlach, SL | 1 |
Wu, C | 1 |
Khurana, N | 1 |
Swientoniewski, LT | 1 |
Abdel-Mageed, AB | 1 |
Li, J | 1 |
Braun, SE | 1 |
Mondal, D | 1 |
Tolstrup, M | 2 |
Søgaard, OS | 2 |
Kent, SJ | 1 |
Reece, JC | 1 |
Petravic, J | 1 |
Martyushev, A | 1 |
Kramski, M | 1 |
De Rose, R | 1 |
Cooper, DA | 1 |
Kelleher, AD | 1 |
Emery, S | 1 |
Cameron, PU | 3 |
Davenport, MP | 1 |
Bosque, A | 1 |
Chan, J | 1 |
Famiglietti, M | 1 |
Greene, WC | 2 |
Kashuba, A | 2 |
Mau, M | 1 |
Ruelas, D | 1 |
Saleh, S | 1 |
Shirakawa, K | 1 |
Siliciano, RF | 3 |
Singhania, A | 1 |
Soto, PC | 1 |
Terry, VH | 1 |
Verdin, E | 1 |
Woelk, C | 1 |
Wooden, S | 1 |
Xing, S | 1 |
Planelles, V | 1 |
Doyon, G | 1 |
Sobolewski, MD | 2 |
Huber, K | 1 |
McMahon, D | 1 |
Mellors, JW | 2 |
Sluis-Cremer, N | 1 |
Ramakrishnan, R | 1 |
Liu, H | 1 |
Rice, AP | 2 |
Klase, Z | 1 |
Yedavalli, VS | 1 |
Houzet, L | 1 |
Perkins, M | 1 |
Maldarelli, F | 1 |
Brenchley, J | 1 |
Strebel, K | 1 |
Liu, P | 1 |
Jeang, KT | 1 |
Bullen, CK | 1 |
Laird, GM | 2 |
Siliciano, JD | 1 |
Cillo, AR | 1 |
Fyne, E | 1 |
Piatak, M | 1 |
Coffin, JM | 2 |
Ho, YC | 1 |
Lucera, MB | 1 |
Tilton, CA | 1 |
Mao, H | 1 |
Tabler, CO | 1 |
Haqqani, AA | 1 |
Tilton, JC | 1 |
Halper-Stromberg, A | 1 |
Lu, CL | 1 |
Klein, F | 1 |
Horwitz, JA | 1 |
Bournazos, S | 1 |
Nogueira, L | 1 |
Eisenreich, TR | 1 |
Liu, C | 1 |
Gazumyan, A | 1 |
Schaefer, U | 1 |
Furze, RC | 1 |
Seaman, MS | 1 |
Prinjha, R | 1 |
Tarakhovsky, A | 1 |
Ravetch, JV | 1 |
Nussenzweig, MC | 1 |
Elliott, JH | 3 |
Wightman, F | 4 |
Ghneim, K | 1 |
Ahlers, J | 1 |
Cameron, MJ | 1 |
Smith, MZ | 1 |
Spelman, T | 2 |
Velayudham, P | 1 |
Brown, G | 1 |
Roney, J | 3 |
Watson, J | 1 |
Prince, MH | 1 |
Hoy, JF | 2 |
Fromentin, R | 1 |
Procopio, FA | 1 |
Zeidan, J | 1 |
Odevall, L | 1 |
Johnstone, RW | 1 |
Martin, BP | 1 |
Sinclair, E | 1 |
Sékaly, RP | 1 |
Lu, HK | 1 |
Gray, LR | 1 |
Ellenberg, P | 2 |
Cheng, WJ | 1 |
Mota, TM | 2 |
Wesselingh, S | 1 |
Gorry, PR | 1 |
Churchill, MJ | 1 |
Lam, S | 1 |
Rooney, CM | 1 |
Jamaluddin, MS | 1 |
Hu, PW | 1 |
Jan, Y | 1 |
Siwak, EB | 1 |
Perdigão, P | 1 |
Gaj, T | 1 |
Santa-Marta, M | 1 |
Barbas, CF | 1 |
Goncalves, J | 1 |
Li, P | 1 |
Kaiser, P | 1 |
Lampiris, HW | 1 |
Kim, P | 1 |
Havlir, DV | 1 |
Baldoni, PL | 1 |
Mollan, KR | 1 |
Newhard, W | 1 |
Cox, K | 1 |
Hudgens, MG | 2 |
Barton, K | 1 |
Hiener, B | 1 |
Winckelmann, A | 1 |
Shao, W | 1 |
Byth, K | 1 |
Lanfear, R | 1 |
Harrington, S | 1 |
Buzon, M | 1 |
Lichterfeld, M | 1 |
Denton, PW | 1 |
Olesen, R | 1 |
Østergaard, L | 1 |
Purcell, DFJ | 1 |
Prince, HM | 1 |
Contreras, X | 1 |
Schweneker, M | 1 |
Chen, CS | 1 |
McCune, JM | 1 |
Martin, J | 1 |
Peterlin, BM | 1 |
Espeseth, A | 1 |
Parker, D | 1 |
Cheema, M | 1 |
Hazuda, D | 1 |
Churchill, M | 1 |
Friedrich, MJ | 1 |
Liberty, AL | 1 |
Choudhary, SK | 1 |
Crooks, AM | 1 |
Parker, DC | 1 |
Anderson, EM | 1 |
Kearney, MF | 1 |
Strain, MC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)[NCT03803605] | Phase 1 | 15 participants (Actual) | Interventional | 2019-02-12 | Completed | ||
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors[NCT03382834] | Phase 2 | 31 participants (Actual) | Interventional | 2018-04-26 | Active, not recruiting | ||
Research In Viral Eradication of HIV Reservoirs[NCT02336074] | Phase 2 | 60 participants (Actual) | Interventional | 2015-11-27 | Completed | ||
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842] | Phase 1/Phase 2 | 107 participants (Actual) | Interventional | 2010-10-06 | Completed | ||
A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy[NCT01319383] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 From The Latent Reservoir (CLEAR) Study[NCT01680094] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
Investigation of the Impact of Inducible, Replication-competent Latent HIV-1 as an Impediment to HIV/AIDS Cure in the Context of Sustained Viral Suppression[NCT04938518] | 222 participants (Anticipated) | Observational [Patient Registry] | 2019-05-01 | Recruiting | |||
Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV[NCT03692611] | 280 participants (Actual) | Interventional | 2019-08-14 | Active, not recruiting | |||
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
A Pilot Study to Assess the Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy[NCT01365065] | Phase 2 | 20 participants (Actual) | Interventional | 2011-05-31 | Active, not recruiting | ||
Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans[NCT02154035] | 90 participants (Actual) | Observational | 2014-05-31 | Completed | |||
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248] | Phase 1 | 6 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection[NCT02071095] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167] | Phase 1 | 6 participants (Actual) | Interventional | 2015-04-07 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol. (NCT03803605)
Timeframe: First day of study treatment through end of study, a total of approximately 36 weeks
Intervention | percentage of participants (Number) |
---|---|
VRC07-523LS + Vorinostat (VOR) | 0 |
Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Cell-associated HIV-1 RNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38
Intervention | log10 copies/million CD4 cells (Mean) |
---|---|
Arm A: Tamoxifen + Vorinostat | 0.06 |
Arm B: Vorinostat Alone | 0.17 |
Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Total HIV-1 DNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38
Intervention | log10 copies/million CD4 cells (Mean) |
---|---|
Arm A: Tamoxifen + Vorinostat | 0 |
Arm B: Vorinostat Alone | -0.04 |
Proportion of participants with new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment (as judged by the core protocol team). The DAIDS AE Grading Table (corrected Version 2.1, July 2017) was used. (NCT03382834)
Timeframe: Measured from study entry through Day 65
Intervention | proportion of participants (Number) |
---|---|
Arm A: Tamoxifen + Vorinostat | 0 |
Arm B: Vorinostat Alone | 0 |
Number of participants with HIV-1 RNA levels measured by single copy assay (SCA) greater or equal to the lower limit of quantification (LOQ). The lower limit of quantification for this study was 0.47 copies/mL. (NCT03382834)
Timeframe: Pre-entry, entry, Day 28, Day 35, Day 38 (5 hours post vorinostat), Day 45, Day 65
Intervention | Participants (Count of Participants) | ||||||
---|---|---|---|---|---|---|---|
Pre-entry SCA >= LOQ | Entry SCA >=LOQ | Day 28 SCA >=LOQ | Day 35 SCA >=LOQ | Day 38 SCA >=LOQ | Day 45 SCA >=LOQ | Day 65 SCA >=LOQ | |
Arm A: Tamoxifen + Vorinostat | 10 | 9 | 11 | 11 | 7 | 9 | 10 |
Arm B: Vorinostat Alone | 6 | 3 | 4 | 5 | 5 | 4 | 5 |
Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks
Intervention | Fold increase pre to post vorinostat (Mean) |
---|---|
Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.19 |
Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16
Intervention | Participants with undetectable outgrowth (Number) |
---|---|
Control (Arm A - ART Only) | 12 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 6 |
The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18
Intervention | HIV-DNA copies/mill CD4+ T cells (log10) (Mean) |
---|---|
Control (Arm A - ART Only) | 2.95 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 3.06 |
"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks
Intervention | Percentage elimination (Mean) |
---|---|
Control (Arm A - ART Only) | -18.25 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 1.50 |
Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
Intervention | % cells CD8+ CD107a+ IFNγ+ (Median) | |
---|---|---|
Post randomisation week 9 | Post randomisation week 12 | |
Control (Arm A - ART Only) | 0.052 | 0.062 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.194 | 0.263 |
Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks
Intervention | % cells CD4+ CD154+ IFNγ+ (Median) | |
---|---|---|
Post randomisation week 9 | Post randomisation week 12 | |
Control (Arm A - ART Only) | 0.006 | 0.006 |
Intervention (Arm B - ART + Vaccines + Vorinostat) | 0.097 | 0.109 |
The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Phase II: VR-DA-EPOCH | 75.6 |
Phase II: DA-R-EPOCH | 82.2 |
The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year
Intervention | percentage of participants (Number) |
---|---|
Phase II: VR-DA-EPOCH | 77.6 |
Phase II: DA-R-EPOCH | 86.7 |
"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months
Intervention | percentage of participants (Number) |
---|---|
Phase II: VR-DA-EPOCH | 67.5 |
Phase II: DA-R-EPOCH | 76.2 |
Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days
Intervention | Mg per day of Vorinostat (Number) |
---|---|
Phase I: VR-DA-EPOCH | 300 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | cells/mm^3 (Median) | |||
---|---|---|---|---|
End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
Phase I: VR-CHOP, Dose Level 1 | -172 | -81 | -16 | 128 |
Phase I: VR-DA-EPOCH, Dose Level 1 | 35.5 | -164.5 | -56 | 604 |
Phase I: VR-DA-EPOCH, Dose Level 2 | -115 | 211 | 275 | 154 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | copies per milliliter (Median) | |||
---|---|---|---|---|
End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
Phase I: VR-CHOP, Dose Level 1 | 28 | 0 | 0 | 0 |
Phase I: VR-DA-EPOCH, Dose Level 1 | -14518 | -4517 | -55116 | 0 |
Phase I: VR-DA-EPOCH, Dose Level 2 | -12.5 | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | cell/mm^3 (Median) | |||
---|---|---|---|---|
End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
Phase I: VR-CHOP, Dose Level 1 | -218 | -190 | -175 | -84 |
Phase I: VR-DA-EPOCH, Dose Level 1 | 92 | -39 | 76 | 169 |
Phase I: VR-DA-EPOCH, Dose Level 2 | -9 | -29 | 31 | 31 |
Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | IU/mL (Median) | |||
---|---|---|---|---|
End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
Phase I: VR-DA-EPOCH, Dose Level 1 | 0 | 0 | 0 | 0 |
Phase I: VR-DA-EPOCH, Dose Level 2 | -2436.1 | -1.92 | -1.92 | -1.15 |
Phase II, DA-R-EPOCH | 0 | -0.28 | 0 | -2.7 |
Phase II, VR-DA-EPOCH | -0.61 | -2.9 | -1.55 | -0.56 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | copies per 100uL (Median) |
---|---|
12-month follow-up | |
Phase II: VR-DA-EPOCH | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | copies per 100uL (Median) | ||
---|---|---|---|
At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
Phase II: DA-R-EPOCH | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
Intervention | median change in copies per mL (Median) | |||
---|---|---|---|---|
End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
Phase II: DA-R-EPOCH | -25 | -22.5 | -18 | -20 |
Phase II: VR-DA-EPOCH | -20 | -87 | -20 | 0 |
The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Death | Life-threatening | Severe | Moderate | Mild | |
Phase II: DA-R-EPOCH | 20.0 | 28.9 | 31.1 | 17.8 | 0 |
Phase II: VR-DA-EPOCH | 28.9 | 37.8 | 20.0 | 8.9 | 2.2 |
Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion
Intervention | Liter/hour (Mean) | ||
---|---|---|---|
Doxorubicin | Etoposide | Vincristine | |
Phase I: VR-DA-EPOCH, Dose Level 1 | 78.6 | 3.0 | 22.4 |
Phase I: VR-DA-EPOCH, Dose Level 2 | 76.0 | 2.4 | 16.8 |
The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment
Intervention | percentage of participants (Number) | |
---|---|---|
Complete response | Partial Response | |
Phase I: Arm C (VR-CHOP) Dose Level 1 | 100 | 0 |
Phase I: VR-DA-EPOCH, Dose Level 1 | 83.3 | 16.7 |
Phase I: VR-DA-EPOCH, Dose Level 2 | 83.3 | 16.7 |
Development of a new cancer within the 5 years of taking their last dose of VOR 400 mg PO.All participants receiving one or more doses of VOR 400 mg PO in any and all Arms of the study. Pre-specified to be reported as one group. (NCT01319383)
Timeframe: From last dose Vorinostat to 5 years afterwards
Intervention | Participants (Count of Participants) |
---|---|
1/Single and Multiple Dose, Step 3 | 0 |
2/Interval Doses (Multiple) Step 4 | 0 |
Participants in Arm 1 and 2 were analyzed in Step 2 for an in vivo increase in resting CD4+ T cell- associated HIV RNA (RCVL) after administration of a single dose of VOR 400 mg PO (NCT01319383)
Timeframe: Arm1: Baseline, Visit 5 and Arm 2: Baseline and Visit 3
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Step 2, Visit 5 | 8 |
2/Interval Dosing, Visit 3 | 4 |
Participants in Arm 1, Step 3 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after 11 doses of VOR 400 mg PO. This cycle was repeated after a 5 - 8 week rest period for a 2nd series and measurement. (NCT01319383)
Timeframe: Baseline, Visit 18, Visit 29
Intervention | Participants (Count of Participants) |
---|---|
Arm 1 - Single and Multiple Dose, Step 3 | 0 |
Participants in Arm 2, Step 4 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after administration of 10 doses of VOR 400 mg PO, given 72 hours apart. (NCT01319383)
Timeframe: Baseline, Visit 9
Intervention | Participants (Count of Participants) |
---|---|
Interval Doses (Multiple) Step 4 | 3 |
Induction of significant in vivo RCI and RCLV response after 2 doses of VOR 400 mg PO administered 48 hours apart or 72 hours apart (NCT01319383)
Timeframe: Baseline, Visit 6
Intervention | Participants (Count of Participants) |
---|---|
Interval Dosing , Step 3 (48 hr Interval) | 0 |
Interval Dosing, Step 3 (72 Hour Interval) | 6 |
DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Steps 2 and 3 | 0 |
2/Interval Dosing, Steps 2, 3 and 4 | 0 |
DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Steps 2 and 3 | 0 |
2/Interval Dosing, Steps 2, 3 and 4 | 0 |
Assess for detectible HIV-1 RNA > 150 copies/mL, confirmed by repeat evaluation, following VOR dose. By standard assay and single copy assay. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 1 week after last VOR dose
Intervention | Participants (Count of Participants) |
---|---|
1/Single & Multiple Dose, Steps 2 and 3 | 0 |
2/Interval Dosing, Steps 2, 3 and 4 | 0 |
the CD38-activation marker on CD8 T-cells (CD8/CD38). (NCT02071095)
Timeframe: Day 8
Intervention | mean fluorescent intensity (MFI) (Mean) |
---|---|
Arm A: Poly-ICLC | 8.69 |
Arm B: Normal Saline | 2.35 |
Natural killer cells or NK cells are part of the innate immune defense against infection and cancer. (NCT02071095)
Timeframe: at 48 weeks
Intervention | cells/µL (Mean) |
---|---|
Arm A: Poly-ICLC | 20.68 |
Arm B: Normal Saline | 19.41 |
Safety measured by number of participants with adverse events. (NCT02071095)
Timeframe: Up to 48 weeks
Intervention | Participants (Count of Participants) |
---|---|
Arm A: Poly-ICLC | 11 |
Arm B: Normal Saline | 3 |
CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline. (NCT02071095)
Timeframe: Baseline, Day 2, Day 4, Day 8, Day 28
Intervention | percent change (Mean) | |||
---|---|---|---|---|
Day 2 | Day 4 | Day 8 | Day 28 | |
Arm A: Poly-ICLC | 102.8 | 134.8 | 161.0 | 199.6 |
Arm B: Normal Saline | 186.3 | 254.7 | 66.33 | 126.7 |
One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8-500 pg/ml. (NCT02071095)
Timeframe: Day 2 and Day 4
Intervention | pg/ml (Mean) | |
---|---|---|
Day 2 | Day 4 | |
Arm A: Poly-ICLC | 381.43 | 450.51 |
Arm B: Normal Saline | 100.65 | 139.39 |
5 reviews available for vorinostat and HIV Coinfection
Article | Year |
---|---|
HIV latency reversal agents: A potential path for functional cure?
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; | 2021 |
Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Topics: Anti-HIV Agents; Bryostatins; CD4-Positive T-Lymphocytes; Depsipeptides; HIV Infections; HIV-1; Huma | 2018 |
Natural product-derived compounds in HIV suppression, remission, and eradication strategies.
Topics: Anti-HIV Agents; Biological Products; Bryostatins; Depsipeptides; Disease Reservoirs; Diterpenes; Dr | 2018 |
The search for an HIV cure: tackling latent infection.
Topics: Bone Marrow Transplantation; Enzyme Inhibitors; HIV Infections; Humans; Hydroxamic Acids; Virus Acti | 2013 |
HDAC inhibitors in HIV.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Histone Deacetylase Inhibitor | 2012 |
7 trials available for vorinostat and HIV Coinfection
Article | Year |
---|---|
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female | 2022 |
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
Topics: Adult; AIDS Vaccines; Anti-Retroviral Agents; Disease Reservoirs; DNA, Viral; Histone Deacetylase In | 2020 |
Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Patient Participation; Qualitative Research; Risk A | 2020 |
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; | 2020 |
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme | 2019 |
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme | 2019 |
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme | 2019 |
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
Topics: Histone Deacetylase Inhibitors; HIV Infections; Humans; Killer Cells, Natural; Panobinostat; Treatme | 2019 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Hu | 2014 |
Broad activation of latent HIV-1 in vivo.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV In | 2016 |
41 other studies available for vorinostat and HIV Coinfection
Article | Year |
---|---|
Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells.
Topics: Ascomycota; Biological Products; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Inf | 2014 |
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
Topics: Broadly Neutralizing Antibodies; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Viremia; | 2022 |
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
Topics: Disulfiram; Drug Therapy, Combination; HIV Infections; Humans; Virus Latency; Vorinostat | 2022 |
Broadening community engagement in clinical research: Designing and assessing a pilot crowdsourcing project to obtain community feedback on an HIV clinical trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antibodies, Monoclonal; Clinical Trials as Topic; Clinical | 2020 |
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection.
Topics: Adult; CD4-Positive T-Lymphocytes; Dendritic Cells; Histone Deacetylase Inhibitors; HIV Infections; | 2020 |
4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
Topics: Anti-HIV Agents; Bryostatins; CD4-Positive T-Lymphocytes; Cell Survival; Drug Synergism; HIV Infecti | 2020 |
Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Topics: Acetylation; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Huma | 2020 |
G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
Topics: Acridines; Anti-HIV Agents; Apoptosis; Bryostatins; CD4-Positive T-Lymphocytes; DNA Damage; DNA Mism | 2020 |
Myc matters in HIV-associated lymphoma.
Topics: HIV Infections; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Vorinostat | 2020 |
Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signaling Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency.
Topics: Anti-HIV Agents; HIV Infections; Humans; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduc | 2021 |
Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency.
Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Histone Deacetylase Inhibito | 2021 |
The Myxobacterial Metabolite Soraphen A Inhibits HIV-1 by Reducing Virus Production and Altering Virion Composition.
Topics: Acetyl-CoA Carboxylase; Anti-HIV Agents; Cell Line, Tumor; HIV Envelope Protein gp120; HIV Infection | 2017 |
The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
Topics: Cells, Cultured; Gene Expression Profiling; GPI-Linked Proteins; Histocompatibility Antigens Class I | 2017 |
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
Topics: Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Female; Hist | 2017 |
Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells.
Topics: Antigens, Viral; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD8-Pos | 2017 |
HIV latency is reversed by ACSS2-driven histone crotonylation.
Topics: Acetate-CoA Ligase; Animals; CD4-Positive T-Lymphocytes; Chromatin; Epigenesis, Genetic; Fatty Acids | 2018 |
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
Topics: Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; CD4-Positive T-Lymphocytes; Cel | 2018 |
Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.
Topics: Antirheumatic Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Endogenous Retroviruses; Gene Exp | 2018 |
Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
Topics: Anti-HIV Agents; Cell Line; Culture Media, Conditioned; Drug Evaluation, Preclinical; Gene Expressio | 2018 |
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
Topics: Acetamides; Adult; CD4-Positive T-Lymphocytes; Cells, Cultured; HEK293 Cells; Histone Deacetylase In | 2013 |
Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Class Ia Phospha | 2014 |
Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV.
Topics: Acetaldehyde Dehydrogenase Inhibitors; CD4-Positive T-Lymphocytes; Cell Line; Cyclin T; Cyclin-Depen | 2015 |
Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA.
Topics: CCAAT-Binding Factor; Chromatin Immunoprecipitation; Core Binding Factor Alpha 2 Subunit; Drug Syner | 2014 |
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Depsipeptid | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation, | 2014 |
Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals.
Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Hydroxami | 2014 |
The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Topics: CD4-Positive T-Lymphocytes; Gene Expression Regulation, Viral; Histone Deacetylase Inhibitors; HIV I | 2014 |
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.
Topics: Animals; Anti-HIV Agents; Antibodies, Neutralizing; CD4-Positive T-Lymphocytes; CTLA-4 Antigen; Hete | 2014 |
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Benzamides; Cell Line; HeLa Cells; Histone Deacetylase Inhibitors; HIV | 2014 |
Experiences and expectations of participants completing an HIV cure focused clinical trial.
Topics: Clinical Trials as Topic; Data Collection; HIV Infections; Humans; Hydroxamic Acids; Patient Partici | 2015 |
Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.
Topics: Anti-HIV Agents; Cells, Cultured; Coculture Techniques; HIV Infections; HIV-1; Humans; Hydroxamic Ac | 2015 |
Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Topics: Antiretroviral Therapy, Highly Active; Benzamides; CD4-Positive T-Lymphocytes; Cells, Cultured; Cycl | 2016 |
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.
Topics: Activating Transcription Factors; CD4-Positive T-Lymphocytes; Cell Line; Gene Expression Regulation, | 2016 |
Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Topics: Acitretin; Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; DEAD Box Protein 58; | 2016 |
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
Topics: Adult; CD4-Positive T-Lymphocytes; Cell Proliferation; Cytokines; Histone Deacetylase Inhibitors; HI | 2016 |
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antineoplastic Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Drug Interaction | 2017 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Hydroxamic Acids; | 2009 |
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins; | 2009 |
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins; | 2009 |
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins; | 2009 |
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.
Topics: CD4-Positive T-Lymphocytes; Cell Line; Cells, Cultured; Genes, Reporter; Green Fluorescent Proteins; | 2009 |
Scientists investigate routing latent HIV from its reservoirs to achieve a cure.
Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Histone Deacetylase In | 2012 |
HIV: Shock and kill.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Virus Latency; Vorinostat | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi | 2012 |